Compare · A vs ILMNV
A vs ILMNV
Side-by-side comparison of Agilent Technologies Inc. (A) and Illumina Inc. (ILMNV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both A and ILMNV operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- A carries a market cap of $48.55B.
- A has hit the wire 11 times in the past 4 weeks while ILMNV has been quiet.
- A has more recent analyst coverage (25 ratings vs 0 for ILMNV).
- Company
- Agilent Technologies Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $48.55B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1999
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Latest A
- Senior Vice President Jonah Prevost Kirkwood covered exercise/tax liability with 58 shares, decreasing direct ownership by 0.41% to 14,050 units (SEC Form 4)
- Senior Vice President Jianmiao Mike Zhang covered exercise/tax liability with 52 shares, decreasing direct ownership by 0.45% to 11,587 units (SEC Form 4)
- President and CEO Padraig Mcdonnell covered exercise/tax liability with 276 shares, decreasing direct ownership by 0.42% to 65,566 units (SEC Form 4)
- Senior Vice President Angelica Riemann covered exercise/tax liability with 56 shares, decreasing direct ownership by 0.10% to 26,747 units (SEC Form 4)
- Agilent to Participate in 9th Annual Evercore Healthcare Conference
- Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme
- Agilent Completes Acquisition of Proscia
- Agilent Launches 5987A MSD with GC Assist for Faster, Smarter GC/MS Workflows
- Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
- Agilent and University of Chicago Launch Center of Excellence for Energy Materials Research
Latest ILMNV
- SVP, Chief Commercial Officer Cunningham Everett was granted 36,860 shares (SEC Form 4)
- Director Ullem Scott B. was granted 205 shares, increasing direct ownership by 5% to 4,550 units (SEC Form 4)
- Amendment: Illumina Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities
- Amendment: Illumina Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits